$435 Million is the total value of Cormorant Asset Management, LP's 46 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ICPT | New | INTERCEPT PHARMACEUTICALS IN | $16,490,000 | – | 50,000 | +100.0% | 3.79% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $13,868,000 | – | 100,000 | +100.0% | 3.19% | – |
| PRTA | New | PROTHENA CORP PLC | $13,409,000 | – | 350,000 | +100.0% | 3.08% | – |
| MRK | New | MERCK & CO. INC NEW | $11,354,000 | – | 200,000 | +100.0% | 2.61% | – |
| SRNE | New | SORRENTO THERAPEUTICS INC | $8,974,000 | – | 700,000 | +100.0% | 2.06% | – |
| ALKS | New | ALKERMES PLC | $8,818,000 | – | 200,000 | +100.0% | 2.03% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $8,260,000 | – | 400,000 | +100.0% | 1.90% | – |
| GLYC | New | GLYCOMIMETICS INC | $7,665,000 | – | 469,400 | +100.0% | 1.76% | – |
| OMER | New | OMEROS CORP | $6,035,000 | – | 500,000 | +100.0% | 1.39% | – |
| GALT | New | GALECTIN THERAPEUTICS INC | $5,328,000 | – | 348,000 | +100.0% | 1.22% | – |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $5,100,000 | – | 400,000 | +100.0% | 1.17% | – |
| RMTI | New | ROCKWELL MED INC | $5,064,000 | – | 400,000 | +100.0% | 1.16% | – |
| REPH | New | RECRO PHARMA INC | $3,660,000 | – | 500,000 | +100.0% | 0.84% | – |
| GNVC | New | GENVEC INC | $3,523,000 | – | 1,329,300 | +100.0% | 0.81% | – |
| AGEN | New | AGENUS INC | $3,170,000 | – | 1,000,000 | +100.0% | 0.73% | – |
| AQXP | New | AQUINOX PHARMACEUTICALS INC | $3,143,000 | – | 246,877 | +100.0% | 0.72% | – |
| ASPX | New | AUSPEX PHARMACEUTICALS INC | $3,076,000 | – | 100,000 | +100.0% | 0.71% | – |
| BIIB | New | BIOGEN IDEC INC | $3,059,000 | – | 10,000 | +100.0% | 0.70% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $2,933,000 | – | 60,000 | +100.0% | 0.67% | – |
| IDRA | New | IDERA PHARMACEUTICALS INC | $1,632,000 | – | 400,000 | +100.0% | 0.38% | – |
| CLTX | New | CELSUS THERAPEUTICS PLCsponsored adr ne | $668,000 | – | 103,000 | +100.0% | 0.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.